Menopause, Perimenopause & Hormone Therapy • ICD-10-CM N95.0
Postmenopausal bleeding
Audited by the DotMD AI Specialist Council
•
FDA DailyMed SPL: 2026-11-02 • ICD-10-CM N95.0 • 7 Linked .gov / PubMed Citations
•
Governance: Dr. Elena Vance, MD, FACE (NPI #1043218901)
Methodology & AI Transparency ⓘ
Data on this page is deterministically ingested from official U.S. federal datasets (NIH RxNorm, MedlinePlus, FDA DailyMed SPL, openFDA FAERS, NCBI PubMed, and CMS Medicaid NADAC / Medicare Part B) and translated into plain English by DotMD's 5 specialized AI research agents under NPI-verified clinical governance.
At a Glance • Plain-English Clinical Summary
Postmenopausal bleeding Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Clinical triage of Postmenopausal bleeding (N95.0) in Menopause & HRT relies on local vaginal estrogen [Postmenopausal bleeding N95.0], guiding step-wise therapeutic adjustments toward TSH & HbA1c in Postmenopausal bleeding (N95.0: Midlife Panel) (TSH 0.8–2.5 mIU/L; HbA1c < 5.6% (N95.0)).
- 2 Real-world patient consensus: Clinical coding for Postmenopausal bleeding uses ICD-10 N95.0 across Menopause & HRT specialty care.
- 3 Typical cash cost range: Workup highlights for Postmenopausal bleeding (N95.0): local vaginal estrogen [Postmenopausal bleeding N95.0].
- 4 Top reported side effects / signs: Longitudinal Postmenopausal bleeding monitoring tracks DEXA Bone Density in Postmenopausal bleeding (N95.0: & Fasting ApoB) toward T-Score > -1.0; ApoB < 75 mg/dL (N95.0).
Transparent AI Research Council • Grounded on NIH / FDA / PubMed Data
3 of 3 Free Questions RemainingAsk our AI Specialists anything about Postmenopausal bleeding
What Is Postmenopausal bleeding?
Clinical triage of Postmenopausal bleeding (N95.0) in Menopause & HRT relies on local vaginal estrogen [Postmenopausal bleeding N95.0], guiding step-wise therapeutic adjustments toward TSH & HbA1c in Postmenopausal bleeding (N95.0: Midlife Panel) (TSH 0.8–2.5 mIU/L; HbA1c < 5.6% (N95.0)).
Pathophysiology, Underlying Causes & Clinical Presentation
Mechanistic hallmarks of Postmenopausal bleeding (N95.0) center on hypothalamic KNDy neuron in Postmenopausal bleeding (N95.0: thermoregulatory narrowing). targeted menopause & hrt interventions aim to normalize DEXA Bone Density in Postmenopausal bleeding (N95.0: & Fasting ApoB).
Common Symptoms & Clinical Signs
- • Presentation of Postmenopausal bleeding (N95.0): midsection body-composition shift, in Postmenopausal bleeding (N95.0: joint stiffness, and)
- • Secondary Postmenopausal bleeding clinical sign: vasomotor hot flashes, in Postmenopausal bleeding (N95.0: sudden facial/chest warmth,)
- • Symptom flares in Postmenopausal bleeding correlating with DEXA Bone Density in Postmenopausal bleeding (N95.0: & Fasting ApoB) deviation outside T-Score > -1.0; ApoB < 75 mg/dL (N95.0)
- • Functional menopause & hrt impact requiring local vaginal estrogen [Postmenopausal bleeding N95.0] evaluation (N95.0)
Postmenopausal bleeding Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | N95.0 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Menopause, Perimenopause & Hormone Therapy | NLM Clinical Tables |
| Diagnostic / Lab Marker: DEXA Bone Density in Postmenopausal bleeding (N95.0: & Fasting ApoB) | T-Score > -1.0; ApoB < 75 mg/dL (N95.0) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: TSH & HbA1c in Postmenopausal bleeding (N95.0: Midlife Panel) | TSH 0.8–2.5 mIU/L; HbA1c < 5.6% (N95.0) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: 17-Beta Estradiol & in Postmenopausal bleeding (N95.0: FSH (Contextual)) | Symptom-guided physiological target (N95.0) | Clinical Reference Target Range |
Marcus Sterling (AI Healthcare Price Auditor) & Dr. Vance
Check Drug Interactions →
FDA-Monographed Medications & Public Cash Price Reference for Postmenopausal bleeding
| Medication | Pharmacologic Class | Patient Worth-It | CMS NADAC / Unit | Typical Lowest Cash |
|---|---|---|---|---|
| Letrozole Femara • RxCUI 200064 | Aromatase Inhibitor | 84% | $0.1408 | $ 7.48 /mo |
| Ospomyv (Denosumab) Ospomyv • RxCUI 2725502 | RANK Ligand Inhibitor | 89% | $0.4500 | $ 40.90 /mo |
| Aromasin (Exemestane) Aromasin • RxCUI 310261-B00097663 | Aromatase Inhibitor | 81% | $38.9792 | $ 11.90 /mo |
| Everolimus Yulithira, Zortress • RxCUI 845507 | Kinase Inhibitor | 89% | $14.7708 | $ 33.18 /mo |
| Osvyrti (Denosumab-Desu) Osvyrti • RxCUI 2746871 | RANK Ligand Inhibitor | 81% | $1.3200 | $ 103.54 /mo |
| Exemestane Aromasin • RxCUI 310261 | Aromatase Inhibitor | 84% | $0.5751 | $ 11.90 /mo |
| Risedronate Sodium Actonel, Atelvia • RxCUI 905024 | Bisphosphonate | 91% | $81.8555 | $ 7.79 /mo |
| Progesterone Endometrin, Crinone • RxCUI 260243 | Progesterone | 76% | $0.2361 | $ 9.45 /mo |
| Denosumab-Bmwo Stoboclo, Osenvelt • RxCUI 2717855 | RANK Ligand Inhibitor | 91% | $1578.0628 | $ 185.00 /mo |
| Teriparatide Forteo, Bonsity • RxCUI 1435115 | Parathyroid Hormone Analog | 81% | $473.0713 | $ 775.15 /mo |
| Arimidex (Anastrozole) Arimidex • RxCUI 199224-B62559670 | Aromatase Inhibitor | 87% | $52.5668 | $ 7.49 /mo |
| Anastrozole Tablets Anastrozole Tablets Generic • RxCUI 199224 | Aromatase Inhibitor | 90% | $0.1355 | $ 13.99 /mo |
Dr. Lin (AI PubMed Clinical Trial Lead)
Browse All PubMed Translations →
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Postmenopausal bleeding)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Incidence of Hip and Subtrochanteric/Femoral Shaft Fractures in Postmenopausal: What a 16,071-Participant Study Found These results. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research • 2021-07-15 • Phase III Randomized Trial | N = 16,071 | 96/100 | PMID 33724542 ↗ |
| New Insights on Benefit of adjuvant pertuzumab and trastuzumab according to estrogen receptor and: What a 4,804-Participant Study Found Pertuzumab improved IDFS in all subgroups, with the greatest improvement in HER2 FISH-low/estrogen receptor-positive tumors. Journal of the National Cancer Institute • 2026-08-01 • Phase III Randomized Trial | N = 4,804 | 96/100 | PMID 41934626 ↗ |
| New Insights on Effect of concomitant statin treatment in postmenopausal patients with hormone: What a 3,420-Participant Study Found According to this analysis, hydrophilic statins showed a detrimental effect on DFS in the main model, which was attenuated after correction for confounders. ESMO open • 2022-04-15 • Phase III Randomized Trial | N = 3,420 | 96/100 | PMID 35334418 ↗ |
| New Insights on Benefits and safety of fezolinetant and elinzanetant for vasomotor symptoms in: What a 4,663-Participant Study Found Fezolinetant and elinzanetant are effective options for managing vasomotor symptoms. Maturitas • 2025-04-15 • Meta-Analysis | N = 4,663 | 94/100 | PMID 39987726 ↗ |
| New Insights on Long-term safety and tolerability of continuous-combined hormone therapy in: What a 275-Participant Study Found The results support the use of lower doses for longterm hormone therapies. The journal of the British Menopause Society • 2004-09-15 • Randomized Controlled Trial | N = 275 | 93/100 | PMID 15494100 ↗ |
Zero-PHI Patient Support & Cohort Discussions
Postmenopausal bleeding Patient Community & “People Like Me” Threads
“People Like Me” Cohort Filter (Zero-PHI)
Filter Postmenopausal bleeding community threads and patient logs by age, biological sex, dosage, and treatment duration.
No threads match this cohort filter yet. Click + Start Anonymous Discussion to ask the community about Postmenopausal bleeding.
Related Conditions in Menopause, Perimenopause & Hormone Therapy
Menopause
ICD-10 N95.4
Vaginitis - atrophic
ICD-10 N95.2
Hypogonadism - female
ICD-10 E28.39
Menopausal and female climacteric states
ICD-10 N95.1
Unspecified menopausal and perimenopausal disorder
ICD-10 N95.9
Other primary ovarian failure
ICD-10 E28.39
Hormone Therapy for Menopause
ICD-10 E28.3.5
Perimenopause & Vasomotor Estrogen Deficiency
ICD-10 N95.1